Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-ß.
Mult Scler Relat Disord
; 66: 104072, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2015867
ABSTRACT
BACKGROUND:
Interferon-ß, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS.RESULTS:
Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs.CONCLUSIONS:
In comparison to other DMTs, we did not find evidence of protective effects of interferon-ß on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-ß. This study does not support the use of interferon-ß as a treatment to reduce COVID-19 severity in MS.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Esclerosis Múltiple Recurrente-Remitente
/
COVID-19
/
Esclerosis Múltiple
Tipo de estudio:
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Humanos
Idioma:
Inglés
Revista:
Mult Scler Relat Disord
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS